免疫治疗在肝细胞癌治疗中的应用

梁瑞峰; 周昌存; 凌嘉浩; 吴贤建

doi:10.3969/j.issn.1009-9905.2026.04.014

中国现代普通外科进展 ›› 2026, Vol. 29 ›› Issue (4) : 332 -336. DOI: 10.3969/j.issn.1009-9905.2026.04.014

学术讲座

免疫治疗在肝细胞癌治疗中的应用

梁瑞峰 ¹ ,
周昌存 ¹ ,
凌嘉浩 ¹ ,
吴贤建 ²

作者信息 +

Author information +

文章历史 +

PDF (1164K)

摘要

关键词

肝细胞癌 / 免疫治疗

Key words

引用本文

引用格式 ▾

[Author(id=1276973278468875248, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={CN=AuthorExt(id=1276973278531789811, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, authorId=1276973278468875248, language=CN, stringName=梁瑞峰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹ 右江民族医学院临床医学院（广西百色 533000）, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1276973278351434729, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, xref=1, ext=[AuthorCompanyExt(id=1276973278364017643, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, companyId=1276973278351434729, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹ 右江民族医学院临床医学院（广西百色 533000）)])]), Author(id=1276973278586315766, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={CN=AuthorExt(id=1276973278657618937, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, authorId=1276973278586315766, language=CN, stringName=周昌存, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹ 右江民族医学院临床医学院（广西百色 533000）, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1276973278351434729, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, xref=1, ext=[AuthorCompanyExt(id=1276973278364017643, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, companyId=1276973278351434729, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹ 右江民族医学院临床医学院（广西百色 533000）)])]), Author(id=1276973278712144892, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={CN=AuthorExt(id=1276973278783448063, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, authorId=1276973278712144892, language=CN, stringName=凌嘉浩, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=¹, address=¹ 右江民族医学院临床医学院（广西百色 533000）, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1276973278351434729, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, xref=1, ext=[AuthorCompanyExt(id=1276973278364017643, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, companyId=1276973278351434729, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=¹ 右江民族医学院临床医学院（广西百色 533000）)])]), Author(id=1276973278837972994, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=176363176@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={CN=AuthorExt(id=1276973278905081860, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, authorId=1276973278837972994, language=CN, stringName=吴贤建, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=², address=² 右江民族医学院附属医院肝胆外科（广西百色 533000）, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1276973278414349292, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, xref=2, ext=[AuthorCompanyExt(id=1276973278426932205, tenantId=1045748351789510663, journalId=1263062189734019109, articleId=1271795291197137562, companyId=1276973278414349292, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=² 右江民族医学院附属医院肝胆外科（广西百色 533000）)])])] 梁瑞峰,周昌存,凌嘉浩,吴贤建. 免疫治疗在肝细胞癌治疗中的应用[J]. 中国现代普通外科进展, 2026, 29(4): 332-336 DOI:10.3969/j.issn.1009-9905.2026.04.014

登录浏览全文

4963

注册一个新账户忘记密码

参考文献

原文顺序 | 出版日期 | 本文引用

[1]	Bray F , Laversanne M , Sung H , et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.

[2]	郑荣寿，陈茹，韩冰峰，等 . 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志， 2024， 46（3）： 221-231. DOI: 10.3760/cma.j.cn112152—20240119—00035.

[3]	原发性肝癌诊疗指南年版编写专家委员会，周俭 . 原发性肝癌诊疗指南（2024年版）[J]. 中国临床医学， 2024， 31（2）： 277-334. DOI: 10.12025/j.issn.1008—6358.2024.20240065.

[4]	王金歌，薛恒辉，秦成坤 . 乙肝表面抗原阴性的乙肝相关性肝癌人群的分类和特征[J]. 中国现代普通外科进展， 2025， 28（4）： 279-283. DOI: 10.3969/j.issn.1009—9905.2025.04.005.

[5]	赫捷，陈万青，沈洪兵，等 . 中国人群肝癌筛查指南（2022，北京）[J]. 中华消化外科杂志， 2022， 21（8）： 971-996. DOI: 10.3760/cma.j.cn115610—20220805—00448.

[6]	文天夫，李川，张晓赟，等 . “健康中国2030”肝癌5年生存率提高15%的关键[J]. 中国普外基础与临床杂志，023， 30（11）： 1281-1283. DOI: 10.7507/1007—9424.202308033.

[7]	王帅飞，魏巧琳，朱小宾，等 . PD—1/PD—L1免疫检查点抑制剂在晚期肝癌治疗中的临床研究进展[J]. 中国医药指南， 2023， 21（27）： 54-56. DOI: 10.15912/j.cnki.gocm.2023.27.044.

[8]	Liao L , Xu H , Zhao Y , et al. Metabolic interventions combined with CTLA—4 and PD—1/PD—L1 blockade for the treatment of tumors: mechanisms and strategies[J]. Front Med—Prc, 2023, 17(5): 805-822. DOI: 10.1007/s11684—023—1025—7.

[9]	周一，梁宾勇，肖震宇 . 免疫检查点抑制剂治疗晚期肝细胞癌的研究进展[J]. 临床外科杂志， 2024， 32（3）： 328-331. DOI: 10.3969/j.issn.1005—6483.2024.03.030.

[10]	邹燕梅，袁响林 . 免疫治疗在肝细胞癌中的应用价值[J]. 临床肝胆病杂志， 2021， 37（8）： 1758-1760. DOI: 10.3969/j.issn.1001—5256.2021.08.004.

[11]	Poorkhani A , Tajaldini M , Ahmadi F , et al. Emerging new immune checkpoint inhibitors in solid tumor immunotherapy[J]. N—S Arch Pharmacol, 2025, 398(9): 11733-11760. DOI: 10.1007/s00210—025—04131—w.

[12]	El—Khoueiry AB , Sangro B , Yau T , et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open—label, non—comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140—6736(17)31046—2.

[13]	Yau T , Park J , Finn RS , et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459): a randomised, multicentre, open—label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90. DOI: 10.1016/S1470—2045(21)00604—5.

[14]	Kaseb AO , Hasanov E , Cao HST , et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open—label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218. DOI: 10.1016/S2468—1253(21)00427—1.

[15]	Zhu AX , Finn RS , Edeline J , et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE—224): a non—randomised, open—label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470—2045(18)30351—6.

[16]	Verset G , Borbath I , Karwal M , et al. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open—Label, Phase II KEYNOTE—224 Trial[J]. Clin Cancer Res, 2022, 28(12): 2547-2554. DOI: 10.1158/1078—0432.CCR—21—3807.

[17]	Merle P , Kudo M , Edeline J , et al. Pembrolizumab as Second—Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow—Up from the Phase 3 KEYNOTE—240 Trial[J]. Liver Cancer, 2023, 12(4): 309-320. DOI: 10.1159/000529636.

[18]	Qin S , Ren Z , Meng Z , et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open—label, parallel—group, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(4): 571-580. DOI: 10.1016/S1470—2045(20)30011—5.

[19]	樊嘉，王征 . 从《原发性肝癌诊疗指南（2024年版）》更新看我国肝癌综合治疗新进展[J]. 中国实用外科杂志， 2024， 44（9）： 984-987. DOI: 10.19538/j.cjps.issn1005—2208.2024.09.03.

[20]	Abou—Alfa GK , Lau G , Kudo M , et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma[J]. NEJM Evid, 2022, 1(8): EVIDoa2100070. DOI: 10.1056/EVIDoa2100070.

[21]	Qin S , Kudo M , Meyer T , et al. Tislelizumab vs Sorafenib as First—Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial[J]. Jama Oncol, 2023, 9(12): 1651-1659. DOI: 10.1001/jamaoncol.2023.4003.

[22]	Pandey A , Cohen DJ . Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection[J]. Immunotherapy—Uk, 2020, 12(5): 287-292. DOI: 10.2217/imt—2020—0014.

[23]	Yau T , Kang Y , Kim T , et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treatedwith sorafenib: The CheckMate 040 randomized clinical trial[J]. Jama Oncol, 2020, 6(11): e204564. DOI: 10.1001/jamaoncol.2020.4564.

[24]	Melero I , Yau T , Kang Y , et al. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5—year results from CheckMate 040[J]. Ann Oncolo, 2024, 35(6): 537-548. DOI: 10.1016/j.annonc.2024.03.005.

[25]	Ren Z , Xu J , Bai Y , et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT—32): a randomised, open—label, phase 2—3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/S1470—2045(21)00252—7.

[26]	Lim HY , Heo J , Kim T , et al. Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22(NCT02519348)[J]. J Clin Oncol, 2022, 40(4_suppl): 436. DOI: 10.1200/jco.2022.40.4_suppl.436.

[27]

Chan SL , Sangro B , Erinjeri JP , et al. Safety analysis by treatment periods from EMERALD—1: A phase 3, randomized, placebo—controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization—eligible unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2024, 42(23_suppl): 65. DOI: 10.1200/JCO.2024.42.23_suppl.65.

[28]	Finn RS , Qin S , Ikeda M , et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. NEJM, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.

[29]

Finn RS , Qin S , Ikeda M , et al. IMbrave150: Updated overall survival (OS) data from a global, randomized, open—label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC) [J]. J Clin Oncol, 2021, 39(3_suppl): 267. DOI: 10.1200/JCO.2021.39.3_suppl.267.

[30]	Xu J , Shen J , Gu S , et al. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open—label, Phase II Trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011. DOI: 10.1158/1078—0432.CCR—20—2571.

[31]	Liu X , Li X , Chu Y , et al. Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review[J]. Front Oncol, 2024, 14: 1280805. DOI: 10.3389/fonc.2024.1280805.

[32]	Qin S , Chan SL , Gu S , et al. Camrelizumab plus rivoceranib versus sorafenib as first—line therapy for unresectable hepatocellular carcinoma (CARES—310): a randomised, open—label, international phase 3 study[J]. Lancet , 2023, 402(10408): 1133-1146. DOI: 10.1016/S0140—6736(23)00961—3.

[33]	Vogel A , Chan SL , Dawson LA , et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow—up[J]. Ann Oncol, 2025, 36(5): 491-506. DOI: 10.1016/j.annonc.2025.02.006.

[34]	Finn R , Kudo M , Merle P , et al. LBA34 Primary results from the phase III LEAP—002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first—line(1L) therapy for advanced hepatocellular carcinoma (aHCC)[Z]. 2022, 33: S1401.

[35]	国家药品监督管理局 . 国家药监局附条件批准艾帕洛利托沃瑞利单抗注射液上市[EB/OL].（ 2024—09—30）. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20240930101946184.html.

[36]	Qin S , Fan J , Yang F , et al. LBA38 Iparomlimab and tuvonralimab (QL1706) with bevacizumab and/or chemotherapy in first—line (1L) treatment of advanced hepatocellular carcinoma(aHCC): A randomized, open—label, phase Ⅱ/Ⅲ study(DUBHE—H—308)[Z]. 2024, 35: S1229-S1230.

[37]

Zhang Y , Guo Y , Xu Z , et al. First—line iparomlimab and tuvonralimab (QL1706) or iparomlimab (QL1604) + bevacizumab (BEV) for unresectable hepatocellular carcinoma (HCC): Updated results from the phase Ib/II DUBHE—H—106 study[J]. J Clin Oncol, 2025, 43(4_suppl): 579. DOI: 10.1200/JCO.2025.43.4_suppl.579.

[38]	Shi G , Huang X , Ma L , et al. First—line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer(ZSAB—TOP): a multicenter, single—arm, phase 2 study[J]. Signal Transduct Tar, 2025, 10(1): 260. DOI: 10.1038/s41392—025—02356—y.